Skip to content

Dianthus Therapeutics DNTH Investment Purchases

Investment Purchases at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$144M-42.6%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$81.17M+13.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$276.27M+230%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$68.97M-67.8%
Biogen logo
BiogenBIIB
$748.8M
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$52.67M

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInvestments.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's investment purchases?
Dianthus Therapeutics (DNTH) reported investment purchases of $238.59M in Q1 2026.
How has Dianthus Therapeutics's investment purchases changed year-over-year?
Dianthus Therapeutics's investment purchases increased by 254.4% year-over-year, from $67.32M to $238.59M.
What does investment purchases mean?
Cash spent purchasing investment securities across all categories.